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Abstract 
Methotrexate (MTX) is an established immunomodulating agent used in low doses (LDMTX) to treat several au-
toimmune diseases. Ulcerative stomatitis (US) may be observed as a long-term LDMTX adverse effect showing a 
wide histopathologic spectrum. A 73-year old female presented with painful oral ulcers of 5 days duration. The pa-
tient had been under treatment for rheumatoid arthritis with LDMTX, while one week before presentation she was 
prescribed ciprofloxacin for a urinary infection. Histopathologic examination of a lingual ulcer revealed a polymor-
phous lymphohistiocytic proliferation with scattered binucleated atypical lymphocytes. Immunohistochemically, 
most cells were of T-cell lineage while the EBER test was negative and a diagnosis of MTX-induced reactive ulce-
ration was rendered. MTX cessation resulted in complete resolution of the ulcers with no recurrences reported so 
far. The clinical and histopathologic features of MTX-induced oral ulcers are not always diagnostic and a detailed 
history and an extensive clinicopathologic investigation may be needed to exclude a lymphoproliferative disorder. 
Key words: Atypical oral ulcers, ciprofloxacin, lymphoproliferative disorders, methotrexate.
doi:10.4317/jced.52909
http://dx.doi.org/10.4317/jced.52909
Article Number: 52909                http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail:  jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System
Katsoulas N, Chrysomali E, Piperi E, Levidou G, Sklavounou-Andriko-
poulou A. Atypical methotrexate ulcerative stomatitis with features of 
lymphoproliferative like disorder: Report of a rare ciprofloxacin-induced 
case and review of the literature. J Clin Exp Dent. 2016;8(5):e629-33.
http://www.medicinaoral.com/odo/volumenes/v8i5/jcedv8i5p629.pdf
J Clin Exp Dent. 2016;8(5):e629-33.                                                                                                                                                                               Methotrexate ulcerative stomatitis
e630
Introduction
Methotrexate (MTX), a well-known antimetabolite, 
functions as a folic acid antagonist and is widely used in 
high doses as a chemotherapeutic agent for the treatment 
of lymphomas, leukemias and some solid tumors (1). 
MTX is a well-established immunomodulating drug that 
is administered in low doses (low-dose MTX-LDMTX), 
with concurrent folate supplementation for the treatment 
of chronic autoimmune and immune-mediated diseases 
such as rheumatoid arthritis, systemic lupus erythemato-
sus and psoriasis (1,2). 
LDMTX administration may be accompanied by a va-
riety of adverse reactions. MTX toxicity is generally 
dose-dependent and rapidly dividing tissues, such as 
the bone marrow and the gastrointestinal tract are most 
commonly affected. Oral ulcerative stomatitis may be 
seen in about 14% of patients demonstrating a wide 
histopathologic spectrum that ranges from non-specific 
ulceration to lichenoid reactions to EBV (+/-) lympho-
proliferative disorders (LPDs) (2,3).
A rare case of MTX-associated ulcerations is presented 
in a patient under long-term LDMTX that histopatholo-
gically exhibited atypical features mimicking a lympho-
proliferative disorder.
Case Report 
A 73-year-old, non-smoker Caucasian female presented 
in the Department of Oral Medicine and Pathology com-
plaining of painful oral lesions of 5-day duration. The 
lesions had been developed after initiation of a per os 
ciprofloxacin course (500 mg 1x3) on 5th therapy day 
for an acute urinary tract Escherichia coli infection diag-
nosed 10 days ago. Two days before the patient’s visit in 
our clinic, the urologist recommended ciprofloxacin re-
placement by metronidazole and cefaclor. According to 
the patient, similar lesions had appeared in the past after 
ciprofloxacin intake, though she was not sure regarding 
the MTX intake at that particular time.
The patient had a known rheumatoid arthritis (RA) his-
tory diagnosed 15 years ago. Medication for the RA ma-
nagement consisted of a low-dose methotrexate therapy 
(2.5mg 1x1/week) supplemented with folic acid (5mg 
1x1/week), prednisone 5mg 1x1/day, in addition to a 
5-courses of rituximab IV (Mabthera inj.sol 500mg/50ml 
1/week x2) administration; the last rituximab IV injec-
tion was given 10 months before the lesions presenta-
tion. Alendronic acid (5600iu/tab 1x1/weekly) and daily 
calcium supplementation were taken for osteoporosis 
management. 
The oral examination revealed multiple ulcerative le-
sions of variable size and irregular shape, located on the 
dorsal and lateral borders of the tongue, the lower lip, 
the alveolar maxillary and mandibular mucosa, which 
were covered by a grey-whitish thick pseudo-membrane 
(Fig. 1), and showed a slightly vegetative ulcer base. 
Fig. 1. Atypical ulcers with irregular borders and yellow fibrinopu-
rulent pseudomembrane on the dorsal surface of the tongue and the 
lower lip mucosa.
There was no evidence of other mucocutaneous lesions 
or cervical lymphadenopathy. LDMTX-associated oral 
ulcers, drug-induced oral reaction, drug-induced erythe-
ma multiforme and a possible atypical viral or bacterial 
infection were considered in the differential diagnosis, 
taking into account the iatrogenic immunosuppression 
history, the abrupt onset of lesions, and the possible drug 
reaction (previous report of ciprofloxacin-induced oral 
lesions). 
Tissue swabs from the ulcers were examined for viral, 
microbial and fungal infection, while a complete labora-
tory investigation was ordered. PCR tests for HSV, CMV 
and EBV were negative. A superimposed yeast infection 
by geotrichum candidum was detected, and interpreted 
to the long-standing iatrogenic immunosuppression. 
Complete blood test results were normal, including the 
folic acid levels. Elevated ESR and CRP levels and sig-
nificant hypogammaglobulinemia (350 mg/dl, normal 
range: 700-1600 mg/dl) were noted. A lingual ulcer inci-
sional biopsy was performed under local anesthesia.
Histopathologic examination revealed extensive ulcera-
tion of the covering stratified squamous epithelium ex-
tended deeply into subjacent striated muscle and adipose 
tissue that showed degeneration. The ulcer base was wi-
dely infiltrated by a dense polymorphous inflammatory 
cell population consisting of lymphocytes, histiocytes 
of variable size, along with neutrophils and scarce eosi-
nophils (Fig. 2a). Among the inflammatory infiltration 
few scattered large binucleated lymphoid cells with 
noticeable atypical features were observed similar to 
Reed-Sternberg cells (Fig. 2b). Both the polymorphous 
inflammatory cells and the Reed-Sternberg-like cells 
exhibited positive immunostaining for T-cell markers 
CD2, CD3, CD4, CD8 and CD15 and negative for B-
cell and NK-cell markers (CD20, CD30, Pax-5, CD56, 
TIA-1 and granzyme) (Figs. 2c-d). LMP-1 immunostai-
ning and EBER test proved to be negative excluding the 
EBV presence. The above findings were suggestive of 
an EBV (-) lymphocytic infiltrate of T-cell phenotype. 
Based upon the patient’s medical history, the complete 
laboratory investigation, the clinical and histopathologic 
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Fig. 2. a) Diffuse mixed inflammatory infiltrate of the lamina propria by lymphocytes of varying size, histio-
cytes, neutrophils, and scarce eosinophils. b) Scattered irregularly-shaped binucleated atypical lymphocytes 
(Reed-Sternberg-like cells, asterisks) among the dense cellular infiltrate (H&E X250). Immunohistochemical 
evaluation revealed, among other markers, positivity for CD2 c) and CD4 d), (immunohistochemical stain 
X400).
findings, a diagnosis of MTX-related non-specific ulce-
rative stomatitis was rendered, possibly induced by the 
recent ciprofloxacin administration. 
With the rheumatologist’s consent, MTX intake was 
ceased and 3 weeks later the oral ulcers had healed com-
pletely (Fig. 3). Two months after MTX withdrawal, the 
drug was restarted, with no evidence of recurrence of the 
oral lesions noted so far.
The patient had provided written informed consent for 
publication of this case report and any accompanying 
images in a scientific journal, after the authors explained 
the possible benefits to dental science.
Discussion
LDMTX adverse reactions may be present in 30-80% of 
the patients, while up to 30% discontinue the treatment 
Fig. 3. Resolution of the lingual and labial ulcers 3 weeks after MTX 
cessation.
as a consequence (2). Common side effects include mye-
losuppresion, nausea, diarrhea, abdominal pain, weight 
loss, and hepatotoxicity. The oral lesions seem to be 
dose-dependent, and a possible early sign of drug toxi-
city. Stomatitis has been referred in approximately 14%, 
and treatment discontinue in 3% of the patients, thus oral 
clinicians may be encountered with a MTX-induced le-
sion more often than previously thought (3). The risk of 
MTX-induced ulcers appears to be increased in patients 
with pre-existing folate deficiency. Elevated drug levels 
in the saliva acting topically are considered to promote 
the oral lesions development. Measurement of the excre-
ted MTX concentration in the saliva has been proposed 
useful in predicting oral ulceration (3,4).
The LDMTX-associated oral ulcers may be apparent 
within the first few weeks, whereas in long-term toxi-
city the lesions can occur even years later in the disease 
course (2). MTX metabolism may be affected by age, 
compromised hepatic or renal function, whereas several 
contraindicated drugs may influence pharmacokinetics 
(1). Among them, quinolones and specifically cipro-
floxacin may promote a reduced renal tubular MTX 
clearance resulting in MTX plasma levels elevation (5). 
In the current case, the ulcerative lesions appeared after 
a 5-day course of ciprofloxacin administration sugges-
ting an acute MTX toxicity, despite the patient was un-
der LDMTX treatment.
LDMTX-associated stomatitis may mimic various oral 
inflammatory conditions, infections or vesiculobullous 
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diseases (3,6). In our case, the differential diagnosis in-
cluded the ciprofloxacin-induced oral minor erythema 
multiforme (EM) due to patient’s history of similar oral 
lesions in the past, as well as herpes-associated EM, due 
to immunosuppresion. The possibility of oral EM see-
med more unlikely based on the clinical features of the 
lesions, the lack of the EM characteristic hemorrhagic 
crusts on the lips vermillion border, and the gingival in-
volvement that usually is not seen in EM.   
The etiology of multiple, deep painful ulcers covered 
by thick necrotic pseudomembrane in medically immu-
nocompromised patients may be associated with HSV, 
CMV or bacterial infection. Among the affected oral si-
tes, dorsal tongue, hard palate, and/or gingiva have been 
referred as frequent locations (7). A possible infection 
was also considered in the differential diagnosis, but the 
microbiologic tests proved to be negative, additionally 
to the fact that the patient was already under a course of 
broad-spectrum antibiotics.
The interval between initiation of MTX therapy and 
MTX-induced LPDs varies, with most patients diagnosed 
after 3-5 years of continuous treatment (8). Several tissues 
and/or internal organs can be affected, including liver, 
kidneys, gastrointestinal mucosa, lung, spleen and skin. 
Besides the MTX-treatment associated neoplastic poten-
tial, the risk for hematopoietic malignancies, most often 
lymphoma, is 2-20-fold increased in patients with RA (3). 
No Age Gender Location Duration Diagnosis/EBV Treatment Authors. Year
1 74 F Tongue 3 months P B-cell LPD/+ D Hashimoto et al. (4) 2015
2 74 F Tongue 2 weeks P B-cell LPD/+ D Hashimoto et al. (4) 2015
3 60 M Gingiva 1 month DLBCL/+ D Horie N et al. (6) 2015
4 75 F Retromolar 
area
- DLBCL/+ D Kudoh et al. (8) 2014
5 80 M Tongue - EBVMCU/+ - Dojcinov et al. (9) 2010
6 60 F Lip - EBVMCU/+ Reduction of 
dose
Dojcinov et al. (9) 2010
7 76 F Gingiva - DLBCL/+ D+ CHOP Ishida et al. (10) 2013
8 44 M Gingiva 1 month HL-like lesion/+ D Kikuchi et al. (11) 2010
9 70 F Gingiva - DLBCL/+ D Uneda et al. (12) 2008
10 69 F Gingiva 3 months HL-like lesion/+ D +CHEMO Tanaka et al. (13) 2008
11 79 F Multiple 2 months DLBCL/+ D Pastor-Nieto et al. (14) 
2009
12 81 F Gingiva 3 months HL/+ D Naidu et al. (15) 2014
Table 1. Reported cases of oral LDMTX-LPDs in the English-language literature.
Among them, MTX administration has been especially 
linked to the development of EBV-related LPDs (9). 
The histopathologic diagnosis of LDMTX oral ulcers 
may be challenging, since the lesions comprise a wide 
spectrum of features (3,9). Twelve cases of oral LPDs 
in patients under LDMTX have been published in the 
English literature (Table 1). Despite the well-established 
incidence of these lesions, to the best of our knowledge, 
this is the first case that was characterized by the finding 
of atypical Reed-Sternberg-like cells sharing features 
similar to a lymphoproliferative disorder, causing diag-
nostic dilemma. Atypical EBV negative cells simulating 
a lymphoma has not been referred in the previously pu-
blished cases, though Kalantzis et al. described atypical 
cells in the ulcer base, but further specific analysis was 
not provided (3). 
Treatment of MTX-induced oral lesions consists of drug 
cessation or dose reduction, supplemented sometimes 
with folate administration, topical palliative therapies 
or conservative surgical excision. The gradual MTX 
polyglutamates clearance may result in healing of the 
ulcers within 2-3 weeks. A close follow-up course is of 
paramount importance, since recurrence of the lesions 
has been referred after a few months of drug removal in 
nearly 50% of patients (3,4,15). 
In conclusion, a careful medical and pharmacologic 
history, along with a recent full blood test investigation 
DLBCL: Diffuse Large B-cell Lymphoma, HL: Hodgkin Lymphoma, EBVMCU:  EBV MucoCutaneous Ulcer,P B-cell PLD: Polymorphous 
B-cell LPD, D: Discontinuation.
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is mandatory in patients under MTX intake. Clinicians 
should be aware of the possible side effects of LDMTX 
in the oral mucosa, as well as the drug pharmacokine-
tics, to avoid prescription of a contraindicated drug that 
may interfere with MTX metabolism.
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